Effect of Xuebijing injection on myocardium during cardiopulmonary bypass: A prospective, randomized, double blind trial.

Cardiac injury Cardioprotection Cardiopulmonary bypass Circulating inflammation Oxidative stress Xuebijing injection

Journal

World journal of clinical cases
ISSN: 2307-8960
Titre abrégé: World J Clin Cases
Pays: United States
ID NLM: 101618806

Informations de publication

Date de publication:
06 May 2022
Historique:
received: 01 09 2021
revised: 23 11 2021
accepted: 16 03 2022
entrez: 6 6 2022
pubmed: 7 6 2022
medline: 7 6 2022
Statut: ppublish

Résumé

Cardiopulmonary bypass (CPB) is an essential procedure for maintaining the blood supply to vital organs in patients undergoing cardiac surgery. However, perioperative cardiac injury related to CPB remains a severe complication in these patients. Cardiac protection is important for patients undergoing CPB. To evaluate the potential cardioprotective efficacy of the Chinese medicine preparation Xuebijing injection (XBJ) in patients undergoing CPB. Sixty patients undergoing cardiac surgery with CPB were randomly allocated to the XBJ and control groups (saline). XBJ was administered intravenously three times: 12 h prior to surgery, at the beginning of the surgery, and 12 h after the second injection. Cardiac function was evaluated by echocardiography 48 h after surgery. Circulating inflammation- and oxidative-stress-related markers were measured. Clinical outcomes related to intensive care unit (ICU) stay were recorded. Compared to control treatment, XBJ was associated with improved PaO Perioperative administration of XBJ was associated with attenuated cardiac injury during CPB, likely

Sections du résumé

BACKGROUND BACKGROUND
Cardiopulmonary bypass (CPB) is an essential procedure for maintaining the blood supply to vital organs in patients undergoing cardiac surgery. However, perioperative cardiac injury related to CPB remains a severe complication in these patients. Cardiac protection is important for patients undergoing CPB.
AIM OBJECTIVE
To evaluate the potential cardioprotective efficacy of the Chinese medicine preparation Xuebijing injection (XBJ) in patients undergoing CPB.
METHODS METHODS
Sixty patients undergoing cardiac surgery with CPB were randomly allocated to the XBJ and control groups (saline). XBJ was administered intravenously three times: 12 h prior to surgery, at the beginning of the surgery, and 12 h after the second injection. Cardiac function was evaluated by echocardiography 48 h after surgery. Circulating inflammation- and oxidative-stress-related markers were measured. Clinical outcomes related to intensive care unit (ICU) stay were recorded.
RESULTS RESULTS
Compared to control treatment, XBJ was associated with improved PaO
CONCLUSION CONCLUSIONS
Perioperative administration of XBJ was associated with attenuated cardiac injury during CPB, likely

Identifiants

DOI: 10.12998/wjcc.v10.i13.4110 PMID: 35665116 PMC: PMC9131227
pubmed: 35665116
doi: 10.12998/wjcc.v10.i13.4110
pmc: PMC9131227
doi:

Types de publication

Journal Article

Langues

eng

Pagination

4110-4118

Informations de copyright

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict-of-interest statement: All authors have no any conflicts of interest.

Références

Anesth Analg. 2010 Nov;111(5):1244-51
pubmed: 20829561
Evid Based Complement Alternat Med. 2014;2014:949254
pubmed: 24778706
Heart. 2000 Apr;83(4):371-3
pubmed: 10722528
J Emerg Med. 1999 Jan-Feb;17(1):95-104
pubmed: 9950395
Sci Rep. 2017 Sep 7;7(1):10807
pubmed: 28883474
Inflamm Res. 2002 Dec;51(12):579-86
pubmed: 12558191
Curr Opin Anaesthesiol. 2014 Jun;27(3):336-43
pubmed: 24670983
Pharmacol Ther. 2010 Jul;127(1):41-52
pubmed: 20398698
J Cardiovasc Pharmacol Ther. 2011 Sep-Dec;16(3-4):290-7
pubmed: 21821531
Best Pract Res Clin Anaesthesiol. 2015 Jun;29(2):137-49
pubmed: 26060026
Int J Mol Sci. 2014 Jun 12;15(6):10541-53
pubmed: 24927144
J Cardiothorac Vasc Anesth. 2008 Dec;22(6):814-22
pubmed: 18948034
Thromb Haemost. 2009 Aug;102(2):240-7
pubmed: 19652874
J Thorac Cardiovasc Surg. 2009 Jul;138(1):206-14
pubmed: 19577081
J Ethnopharmacol. 2013 May 20;147(2):426-33
pubmed: 23524166
Eur J Cardiothorac Surg. 2009 Feb;35(2):235-40
pubmed: 19084419
J Thorac Cardiovasc Surg. 2003 Jan;125(1):178-83
pubmed: 12539002
Chin J Integr Med. 2018 Nov;24(11):815-821
pubmed: 30062633
J Thorac Cardiovasc Surg. 2014 Nov;148(5):2373-2379.e1
pubmed: 24290712
Front Pharmacol. 2018 Mar 29;9:300
pubmed: 29651245
Cardiovasc Pathol. 2001 Sep-Oct;10(5):241-5
pubmed: 11673063
Evid Based Complement Alternat Med. 2013;2013:804940
pubmed: 24369483
J Pak Med Assoc. 2009 Dec;59(12):819-22
pubmed: 20201171
Eur J Cardiothorac Surg. 2004 Mar;25(3):304-11
pubmed: 15019653
J Tradit Chin Med. 2011 Mar;31(1):46-9
pubmed: 21563507
Exp Lung Res. 2010 May;36(4):211-8
pubmed: 20426529
Exp Ther Med. 2017 Jun;13(6):3408-3416
pubmed: 28588676
Eur J Cardiothorac Surg. 2002 Feb;21(2):232-44
pubmed: 11825729
Artif Organs. 2012 Nov;36(11):939-42
pubmed: 23121201
Oxid Med Cell Longev. 2015;2015:189863
pubmed: 25722792

Auteurs

Zhe-Hao Jin (ZH)

Department of Anesthesiology, The 2nd Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang Province, China.

Xiao-Qing Zhao (XQ)

Department of Anesthesiology, The 2nd Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang Province, China.

Hai-Bin Sun (HB)

Department of Anesthesiology, The 2nd Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang Province, China.

Jing-Li Zhu (JL)

Department of Anesthesiology, The 2nd Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang Province, China.

Wei Gao (W)

Department of Anesthesiology, The 2nd Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang Province, China. gaowei20055@126.com.

Classifications MeSH